TScan Therapeutics signs separation agreements with departing executives

TScan Therapeutics, Inc. has entered into separation agreements with its Chief Financial Officer and Chief Medical Officer, formalizing departures that were first disclosed in September. The company filed a Form 8-K with the Securities and Exchange Commission on September 30, 2026, detailing the terms of the exits for Jason A. Amello and Chrystal Louis, M.D., MPH.

The departures are part of a strategic reorganization previously announced by the Waltham, Massachusetts-based firm. On September 24, 2026, the company signed a separation agreement with Dr. Louis, and on September 25, 2026, it signed a similar agreement with Mr. Amello. Under these contracts, each executive's employment will end on November 1, 2026, or earlier if they begin other employment, consulting work, or paid board service. Until their respective separation dates, both executives will continue to receive their base salaries and applicable employee benefits.

Both executives retain the right to receive termination-related payments and benefits that were previously disclosed by the company. Additionally, each is eligible for a specific lump-sum cash award tied to a company milestone under the November 2025 retention program. This program, referred to in the filing as the 2025 Retention Program, outlines conditions for these additional payments.

Mr. Amello is entitled to a lump-sum cash award of $85,000 if a certain company milestone is achieved before his separation date. Dr. Louis is entitled to a lump-sum cash award of $125,000 under the same conditions. The filing notes that these descriptions are qualified by the full text of the separation agreements, which are not included in the current report.

The full text of the separation agreements will be filed as exhibits to TScan Therapeutics' Quarterly Report on Form 10-Q for the quarter ending September 30, 2026. The document was signed by Gavin MacBeath, Ph.D., who serves as the company's Chief Executive Officer and Principal Executive Officer.

TScan Therapeutics is an emerging growth company incorporated in Delaware. Its voting common stock trades on The Nasdaq Global Market under the symbol TCRX. The company's principal executive offices are located at 830 Winter Street in Waltham, Massachusetts.